JPWO2023064769A5 - - Google Patents
Info
- Publication number
- JPWO2023064769A5 JPWO2023064769A5 JP2024521784A JP2024521784A JPWO2023064769A5 JP WO2023064769 A5 JPWO2023064769 A5 JP WO2023064769A5 JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024521784 A JP2024521784 A JP 2024521784A JP WO2023064769 A5 JPWO2023064769 A5 JP WO2023064769A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- subject
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254447P | 2021-10-11 | 2021-10-11 | |
| US63/254,447 | 2021-10-11 | ||
| PCT/US2022/077908 WO2023064769A1 (en) | 2021-10-11 | 2022-10-11 | Methods of effecting a hemodynamic change by administering an anti-npr1 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024537284A JP2024537284A (ja) | 2024-10-10 |
| JP2024537284A5 JP2024537284A5 (https=) | 2025-12-22 |
| JPWO2023064769A5 true JPWO2023064769A5 (https=) | 2025-12-22 |
Family
ID=84045029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521784A Pending JP2024537284A (ja) | 2021-10-11 | 2022-10-11 | 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240327539A1 (https=) |
| EP (1) | EP4415820A1 (https=) |
| JP (1) | JP2024537284A (https=) |
| KR (1) | KR20240099275A (https=) |
| CN (1) | CN118159290A (https=) |
| AU (1) | AU2022363841A1 (https=) |
| CA (1) | CA3234238A1 (https=) |
| CL (1) | CL2024001071A1 (https=) |
| CO (1) | CO2024005662A2 (https=) |
| IL (1) | IL311917A (https=) |
| MX (1) | MX2024004302A (https=) |
| WO (1) | WO2023064769A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
| WO2024251255A1 (zh) * | 2023-06-08 | 2024-12-12 | 江苏恒瑞医药股份有限公司 | 抗npr1抗体及其医药用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US9090695B2 (en) | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| MY205168A (en) | 2018-10-23 | 2024-10-04 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
| EA202193345A1 (ru) * | 2019-06-12 | 2022-03-16 | Новартис Аг | Антитела к рецептору-1 натрийуретического пептида и способы их применения |
| US12325752B2 (en) * | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
-
2022
- 2022-10-11 IL IL311917A patent/IL311917A/en unknown
- 2022-10-11 EP EP22798040.6A patent/EP4415820A1/en active Pending
- 2022-10-11 CN CN202280068577.9A patent/CN118159290A/zh active Pending
- 2022-10-11 CA CA3234238A patent/CA3234238A1/en active Pending
- 2022-10-11 WO PCT/US2022/077908 patent/WO2023064769A1/en not_active Ceased
- 2022-10-11 US US18/045,671 patent/US20240327539A1/en not_active Abandoned
- 2022-10-11 MX MX2024004302A patent/MX2024004302A/es unknown
- 2022-10-11 AU AU2022363841A patent/AU2022363841A1/en active Pending
- 2022-10-11 KR KR1020247015704A patent/KR20240099275A/ko active Pending
- 2022-10-11 JP JP2024521784A patent/JP2024537284A/ja active Pending
-
2024
- 2024-04-10 CL CL2024001071A patent/CL2024001071A1/es unknown
- 2024-04-30 CO CONC2024/0005662A patent/CO2024005662A2/es unknown
- 2024-10-11 US US18/913,899 patent/US20250034279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2361917T3 (es) | Inhibidores del receptor 1 del factor de crecimiento de fibroblastos y procedimiento de tratamiento de los mismos. | |
| DK1976886T3 (en) | Means and methods for the treatment of tumor diseases | |
| US20230203202A1 (en) | Proteins binding nkg2d, cd16 and 5t4 | |
| JP2015526458A5 (https=) | ||
| CN114558129A (zh) | 用于降低心血管风险的方法 | |
| RU2014106652A (ru) | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения | |
| EP3294769B1 (en) | Treatment for multiple myeloma (mm) | |
| JP2008540456A (ja) | 血管疾患の治療 | |
| US20210403573A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells | |
| KR20240099275A (ko) | 항-ｎｐｒ１ 항체를 투여하여 혈류역학적 변화를 일으키는 방법 | |
| JPWO2023064769A5 (https=) | ||
| JP2018533588A (ja) | 治療パラダイム | |
| JP7093940B2 (ja) | 全身性強皮症治療用医薬組成物 | |
| NO340627B1 (no) | Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff. | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| JP2022125157A (ja) | 抗－ｖｅｇｆｒ－２抗体 | |
| WO2022159875A1 (en) | Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah) | |
| CN115814076A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 | |
| US20260102490A1 (en) | Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma | |
| EA028718B1 (ru) | Способ лечения артериальной гипертензии или косвенно или прямо связанных заболеваний | |
| WO2025237307A1 (zh) | 凝血因子FXI/FXIa抑制剂用于治疗肺动脉高压和/或高血压 | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 | |
| JPWO2021127525A5 (https=) | ||
| WO2025226637A1 (en) | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor | |
| HK40103606A (zh) | 抗cd6单克隆抗体在预防由高炎症反应引起的细胞和器官损伤中的用途 |